Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4. The post MindMed Announces Positive Results from Phase 2b...
With only a few weeks left in the year, concern was rising over why MAPS PBC hadn’t yet submitted its NDA. All that, however, was put...
A Seattle doctor is not giving up when it comes to the rescheduling of psilocybin. While the focus on rescheduling cannabis is talked about constantly,...
Moderna and Merck reported Thursday that their personalized melanoma cancer vaccine plus Keytruda approach delivered “continued improvement” in reducing...
On this episode of the Psychedelic Invest Podcast, host Bruce Eckfeldt is joined by Kyle Buller, the Chief of Training and Clinical Education for Psychedelics...
PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLD) (“PharmaDrug” or the “Company“), a specialty pharmaceutical company focused on the research, development...
Ishikawa, Japan — Various molecular systems have been developed by researchers for photoinduced (i.e., light-driven) electron transfer, including supramolecules,...
MAPS Public Benefit Corporation (“MAPS PBC”), a clinical-stage company dedicated to changing the way mental health conditions are treated, announced...
The FDA has 60 days to decide if the application will be accepted for review. The post MAPS Submits New Drug Application to FDA for MDMA...
Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and...
Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy. The post Breaking News: MAPS Files New Drug Application...
Historic filing marks first New Drug Application submission for any psychedelic-assisted therapy. The post Breaking News: MAPS Files New Drug Application...
Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company“), a clinical‐stage natural psychedelic drug development...
Cody Shandraw is a managing partner at Ambria Capital and Co-Founder of Healing REIT, both of which are working to provide better solutions to healthcare....
The Administrator of the Drug Enforcement Administration (DEA) has issued a temporary order to schedule six synthetic cannabinoids in schedule I under...